Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA).

"We are very pleased with these preliminary results from our VMAT2 Phase IIa study," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences.  "Over the twelve days of treatment with our VMAT2 inhibitor, subjects showed a marked improvement in abnormal hyperkinetic movements. The drug was generally well tolerated and showed the desired pharmacokinetic profile previously demonstrated in two Phase I studies."

The open-label Phase IIa study was designed to assess efficacy, safety and tolerability of NBI-98854 in up to ten schizophrenia patients who have moderate to severe Tardive Dyskinesia over a twelve-day period. The impact on the dyskinesia was assessed utilizing the Abnormal Involuntary Movement Scale (AIMS). The dosing regimen consisted of three, four-day periods of NBI-98854 at increasing doses of 12.5mg, 25mg and 50mg administered once daily. After discontinuation of NBI-98854, a seven-day washout period was followed by a final assessment. The study inclusion criteria included a baseline total score of at least nine on the first seven components of the AIMS, with at least two body regions receiving scores of moderate (3) or severe (4). For this cohort of six subjects, the mean baseline score was 14.3 (AIMS total items 1-7, possible total score of 28).

After the twelve days of dosing in six subjects, the mean AIMS score decreased to 8.4, a reduction of 41.3%. Reduction in abnormal involunta
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... December 16, 2014 “Never say, ... Philipps- Universität Marburg’s Department of Physics, advises young ... the newly released SPIE Women in Optics ... too shy to ask questions.” , In the ... and mathematics) occupations ranging from university professor and ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... ... to organizations representing the best web sites dedicated to health care. , ... Boston, Mass. (PRWEB) November 10, ... fifth consecutive eHealthcare Leadership Award and seventh overall at the 10th Annual Healthcare Internet ...
... ... of its annual Student Award Program , ... Boston, Mass. (Vocus) -- The Adventus Group , a ... University of Massachusetts Amherst to recognize emerging environmental scientists during the 25th Annual International ...
... , NEW YORK, Nov. 9 "Micro cap and small cap ... and exposure as a ,buying window, opens and to take advantage ... metals," states Herbert Haft, President of The Haft Group, Inc, Manhattan ... and small cap equities market in the US and Canada, and ...
Cached Biology Technology:CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 2University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 3University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders 4Haft Group says Bullish Commodity Market Triggers Small and Micro-cap Upsurge 2
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... feature for easy storage. Linkage: This CLS number ... match Cornings product number. If showing no availability ... (Z70,947-6) or contact customer service for assistance. ID ... area 55 cm 2 D H ...
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
...
Biology Products: